Murat Kalayoglu’s Post

The industry is right on the cusp of blowing allogeneic cell therapies wide open! Issues with allo cell potency and persistence are slowing becoming a thing of the past: “Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy.” IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Cartesian Therapeutics celebrates a Phase II win with their mRNA CAR-T therapy for myasthenia gravis. Descartes-08 showed a 71% improvement in patients, surpassing the 25% in the placebo group. Notably, this therapy does not require lymphodepleting chemotherapy, allowing for outpatient administration. Insight - Cartesian secured $130M in financing, fueling further development of their innovative mRNA platform and expanding into other autoimmune diseases like systemic lupus erythematosus. Key questions - How will Cartesian's mRNA CAR-T therapy reshape treatment for autoimmune diseases? What implications does this have for future cell therapies? #Biotech #CAR_T #AutoimmuneDisease #HealthcareInnovation #CartesianTherapeutics

Brainstorm Cell Therapeutics Announces Peer-reviewed Publication of #Biomarker Data from NurOwn's® Phase 3 Clinical Trial in #ALS. NurOwn treatment resulted in a positive impact on important #CSF biomarkers relevant to ALS compared to placebo. Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS. https://lnkd.in/gv7R7FY3

Another milestone not only for solid tumors and #allogeneic #NK #celltherapy, but also for cryopreserved starting material! The #cryopreservation process allows to maintain significant cellular cytotoxicity, and potentially making hundreds of thousands of #NKcell doses from a single donor. Learn how CPC Services can help your #clinicaltrial patient sample processing and cryopreservation and storage of starting material. www.cpcservices.com https://lnkd.in/eSPurzXs #immunotherapy #cancerresearch #clinicalresearch

All that you need to know about enabling #mRNA delivery for transient protein expression with minimal toxicity via #LNP to address a range of manufacturing and safety challenges facing CAR-T Cell Therapy. #nanomedicine #cartcelltherapy #celltherapy

Significant Advancement in DMD Treatment by Sarepta Therapeutics! While Pfizer's Phase 3 CIFFREO trial for DMD therapy faced setbacks, last Thursday marked a positive shift with Sarepta's ELEVIDYS label receiving FDA approval, expanding treatment options significantly.  Previously, only DMD boys between aged 4 and 5 were FDA approved to receive the therapy, and now, all young DMD boys and men aged 4 and above will have access per the FDA expansion. In addition, previously, there were strict ambulatory restrictions whereby if the child required assistance with ambulation, they were excluded from having access, whereby, now, this milestone FDA expansion includes full approval for non-wheelchair-dependent patients and accelerated approval for those who are wheelchair-dependent. Despite initial challenges, secondary clinical trial results demonstrating improved motor functions supported this decision, bringing renewed hope to families affected by this devastating disease. We anticipate many DMD boys who were denied access over the past year, may now meet guidelines for access to this potentially life-changing treatment option per the FDA expansion. Symphony Benefit Solutions is staying on top of developing stories like this in the gene and cell therapy arena. We are excited for the 7/1 launch of our fully integrated program, which will tackle high-cost gene and cell therapy treatments while remaining at the forefront of this rapidly changing environment. Reach out to us to learn more about how Symphony Benefits Solution can help at [email protected] This development highlights the continued progress and breakthroughs in the fight against DMD.  #DMD #GeneTherapy #SareptaTherapeutics #FDAApproval #MedicalBreakthrough #SymphonyBenefitSolutions

An Exciting Development in Cell Therapy for Autoimmune Disorders! Century Therapeutics, Inc. secures Funding, and acquires Clade Therapeutics, to support the expansion of its autoimmune pipeline! Here are some of the highlights: 🚀The incorporation of three preclinical-stage programs from Clade's αβ iT platform, spanning cancer and autoimmune diseases (such as Myasthenia Gravis), will address critical unmet needs! 🔍 The CALiPSO-1 trial for SLE, (an innovative iPSC-derived iNK cell therapy) is poised for additional regulatory filings in 2024. 💰A $60 million private placement led by Bain Capital ensures Century Therapeutics, Inc.'s financial stability into 2026, fueling the development of autoimmune therapies 🗣️CEO, Brent Pfeiffenberger, states "Today's news signifies a transformative milestone for Century, as we accelerate and broaden our research and development initiatives in autoimmune diseases and iPSC-derived cell therapy on a larger scale" Stay tuned as Century Therapeutics, Inc develops its autoimmune disease treatments! #CenturyTherapeutics #Innovation #AutoimmuneDisease #celltherapy #CART #SLE #lupus #biotechnology

FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors On June 13, 2024, the Food and Drug Administration granted accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy. #fda #drugapproval #oncology https://lnkd.in/g2tx7wg6

By enabling messenger RNA (mRNA) delivery for transient protein expression with minimal toxicity, lipid nanoparticles have the potential to address a range of manufacturing and safety challenges facing the CAR T-cell therapy field. As new studies are published demonstrating their advantages, it may not be long before LNPs start to displace electroporation in the non-viral CAR T delivery field. Read this article to learn more about the role LNPs are playing to advance CAR T cell therapies. #mrna #LNP #cartcelltherapy #tcells

We need to further define the terms 'organoids' and 'spheroid' cells. Personally, I disagree with labeling patient-derived cells as 'organoids,' as discussed in this paper. However, this patient-derived cell screening approach could provide a valuable opportunity to discover novel therapeutic options, despite some limitations in immuno-oncology. https://lnkd.in/geVM3pKm